Urolithiasis: A Comprehensive Clinical Review
Definition
Urolithiasis is a condition characterized by the formation of solid concretions, or stones, anywhere within the urinary tract, including the kidneys, ureters, bladder, or urethra (6). It is crucial to recognize that this is not merely an isolated, painful event but a complex, often chronic medical condition. The presence of a stone frequently serves as a clinical sentinel, signaling underlying systemic metabolic diseases such as hyperparathyroidism, metabolic syndrome, or inherited genetic disorders (3). Therefore, the discovery of a urinary stone mandates a broader clinical perspective beyond simple removal, prompting investigation into its root cause to prevent recurrence and manage associated comorbidities.
Epidemiology
Urolithiasis is a significant global health issue, and its prevalence is unequivocally rising, mirroring the global epidemic of obesity and metabolic syndrome (44). Malaysia is situated squarely within the global "stone belt," a geographical region with a disproportionately high incidence of the disease. This is largely attributed to a hot, tropical climate that promotes chronic dehydration and the formation of highly concentrated urine, a primary driver of stone formation (48).
Malaysian Context: The epidemiological landscape in Malaysia tells a story of rapid socioeconomic transition. The incidence of urolithiasis has surged dramatically, from under 40 per 100,000 population in the 1960s to over 442 per 100,000 by the 1990s (44). A 2022 community-based study in Sarawak, utilizing ultrasonography for screening, reported a prevalence of 4.04%, confirming it as a common condition (49). Critically, there has been a profound shift in the anatomical location of stones. Historically, lower tract (bladder) stones were common, often linked to childhood nutritional deficiencies. Today, upper tract stones (in the kidney and ureter) constitute the vast majority of cases (85-93%). This epidemiological shift is a direct consequence of improved economic status and the adoption of "westernized" dietary patterns, which are rich in animal protein and sodium—both potent promoters of stone formation (44). This rising tide of urolithiasis places a considerable strain on the Malaysian healthcare system, leading to increased emergency department visits, hospital admissions, and costly surgical interventions.
Global Context: The lifetime risk of developing a kidney stone is substantial, estimated at 7-13% in North America, 5-9% in Europe, and a wide range of 1% to 19.1% across Asia (13). This variability underscores the powerful influence of local dietary habits, climate, and genetic backgrounds on stone formation.
Demographics:
Age: The peak incidence occurs in the most productive years of life, typically between 30 and 60 years of age (8). This has significant socioeconomic consequences, leading to lost workdays and reduced productivity.
Gender: While historically more common in men with a 3:1 ratio, this gender gap is rapidly narrowing. A recent Malaysian study found a ratio of just 1.2:1 (49). This convergence is thought to be driven by parallel changes in lifestyle and dietary habits between genders, diminishing the previously observed protective effects in women.
Ethnicity: Local data often reflects the demographics of the study's catchment area. For instance, a study in Kelantan, a state with a predominantly Malay population, found that 91.1% of stone-forming patients were of Malay ethnicity (4). Understanding local demographic patterns is crucial for targeted public health messaging.
Etiology
The formation of stones is a multifactorial disease, resulting from a complex interplay of intrinsic (non-modifiable) and extrinsic (modifiable) risk factors. A thorough risk factor assessment is the first step in preventing recurrence (16).
Non-Modifiable Risk Factors
Genetic Predisposition: A positive family history is one of the strongest predictors of stone disease, with genetics estimated to account for approximately 50% of the overall risk (54).
Monogenic Diseases: In a minority of patients, stone formation is the direct consequence of a single, high-impact gene mutation. Classic examples include Cystinuria, an autosomal recessive disorder from mutations in the SLC3A1 and SLC7A9 genes, leading to massive urinary leakage of the poorly soluble amino acid cystine, and Primary Hyperoxaluria, a severe genetic liver disorder causing massive overproduction of oxalate (6, 18).
Polygenic Risk: For the vast majority of common calcium stone formers, the genetic risk is polygenic. This means multiple common gene variants, each with a small individual effect, combine to create a susceptible phenotype. Genome-wide association studies (GWAS) have identified variants in genes crucial for ion transport and inhibitor production, such as CASR (calcium-sensing receptor), VDR (vitamin D receptor), and UMOD (which codes for the protective protein uromodulin) (58).
Anatomical Abnormalities: Any structural defect in the urinary tract that causes urinary stasis creates a permissive environment for stone formation. Impaired urine flow allows crystals more time to grow and aggregate.
Key examples include congenital Ureteropelvic Junction (UPJ) obstruction, anatomical variants like a horseshoe kidney, and acquired conditions like ureteral strictures from prior surgery or infection (2, 7).
Modifiable & Environmental Risk Factors
Dietary Influences: Diet is the most critical modifiable factor and the primary target for prevention.
Insufficient Fluid Intake: Universally recognized as the single most important risk factor. Low fluid intake leads to low urine volume, which concentrates all solutes and dramatically increases urinary supersaturation (6).
High Sodium Intake: A high-salt diet is a powerful promoter of calcium stones. The renal tubules handle sodium and calcium in a linked fashion; therefore, high sodium excretion forces a corresponding increase in calcium excretion (hypercalciuria) (6).
High Animal Protein Intake: Diets rich in meat, poultry, and fish impose a significant acid load on the body. This lowers urine pH (promoting uric acid stones) and reduces the excretion of citrate, a key urinary inhibitor. It also directly increases the urinary excretion of calcium and uric acid (6).
High Oxalate Intake: A major risk factor for the most common stone type, calcium oxalate. Foods particularly rich in oxalate include spinach, rhubarb, beets, nuts, and tea (6).
Dietary Calcium (A Common Misconception): A low-calcium diet increases the risk of calcium oxalate stones. Calcium in the gut binds to dietary oxalate, preventing its absorption. With low dietary calcium, more oxalate is absorbed into the bloodstream and excreted in the urine, leading to hyperoxaluria. A normal dietary calcium intake (1000-1200 mg/day) is therefore recommended (11).
Lifestyle and Comorbidities:
Obesity and Metabolic Syndrome: There is a robust and consistent link between increasing body mass index (BMI) and stone risk. Insulin resistance, a core feature of metabolic syndrome and type 2 diabetes, impairs the ability of renal tubular cells to produce ammonia (ammoniagenesis). This reduces the kidney's capacity to excrete acid, resulting in persistently acidic urine, which is a major driver for uric acid stone formation (6, 53).
Medication-Induced:
Topiramate, Acetazolamide: These carbonic anhydrase inhibitors cause a metabolic acidosis and drastically reduce urinary citrate excretion, creating a highly favorable environment for calcium phosphate stone formation (11).
Loop Diuretics (e.g., Furosemide): While useful for managing fluid overload, long-term use can cause significant hypercalciuria, increasing the risk of calcium stones (20).
Certain Antibiotics (Ceftriaxone, Sulfonamides): Ceftriaxone can precipitate with calcium in the urine, while older sulfonamides can crystallize in acidic urine, forming drug-based stones (6).
Pathophysiology
Stone formation (lithogenesis) is a sophisticated, multi-step biological process, not simple precipitation. It is driven by a fundamental imbalance between factors that promote crystallization and those that inhibit it.
Physicochemical Cascade: The absolute prerequisite for stone formation is supersaturation of urine with stone-forming solutes like calcium, oxalate, or uric acid (6). This state, driven by low urine volume or high solute excretion, allows for nucleation, the initial formation of a stable crystal nidus from a liquid phase. For this microscopic crystal to become a clinical problem, it must undergo crystal growth (deposition of more solute onto its surface) and crystal aggregation (clumping together with other crystals) to form a macroscopic mass that is retained within the urinary tract (16).
Randall's Plaque: The "fixed particle" theory provides a compelling explanation for the origin of most common calcium oxalate stones. The process begins not in the urine, but deep within the kidney tissue with the formation of a Randall's plaque. This is an interstitial deposit of calcium phosphate (apatite) that originates in the basement membrane of the thin loop of Henle. Over time, this plaque grows, extends through the kidney's interstitium, and eventually erodes through the delicate urothelial lining of the renal papilla, becoming exposed to pelvic urine. This fixed plaque then serves as an ideal, pre-formed scaffold for the heterogeneous nucleation of calcium oxalate crystals from the supersaturated urine, leading to the formation of an attached stone (6).
Imbalance of Promoters and Inhibitors:
Promoters: These are urinary factors that drive the lithogenic cascade forward. They include low urine volume, high urinary excretion of calcium (hypercalciuria), oxalate (hyperoxaluria), and uric acid (hyperuricosuria), and abnormal urine pH (3).
Inhibitors: Healthy urine contains powerful natural inhibitors that prevent crystal formation even in a supersaturated state. Citrate is a crucial small molecule inhibitor that chelates calcium in the urine, forming a soluble complex and reducing the amount of free calcium available to bind with oxalate. Tamm-Horsfall protein (uromodulin), a macromolecule produced by the kidney tubules, is a potent inhibitor of crystal aggregation, effectively coating crystal surfaces to prevent them from clumping together (3, 27). Stone disease is fundamentally a state of inhibitor failure.
Inflammation and the Gut-Kidney Axis:
Inflammation: Lithogenesis is not a sterile, passive process. Crystals are biologically active and incite an inflammatory response. When calcium oxalate crystals adhere to renal tubular cells, they cause direct cellular injury and oxidative stress. This triggers the activation of the NLRP3 inflammasome, a key intracellular danger sensor. Activated NLRP3 leads to the release of potent pro-inflammatory cytokines like Interleukin-1β (IL-1β), which recruits immune cells and perpetuates a cycle of inflammation, tubular injury, and potential renal fibrosis (31, 32).
Gut-Kidney Axis: The gut microbiome is a key regulator of stone risk, particularly for calcium oxalate stones. The gut bacterium Oxalobacter formigenes uniquely uses oxalate as its energy source, degrading it in the gut and preventing its absorption. The absence of this bacterium, often due to antibiotic use, is a significant risk factor for hyperoxaluria and stone formation (40).
Clinical Presentation
The clinical presentation of urolithiasis is classic but can be mimicked by other conditions. The nature and location of the pain are paramount diagnostic clues.
Diagnostic Clues
Renal Colic: The hallmark symptom of an obstructing ureteric stone is renal colic. This is an acute, excruciatingly severe, colicky (waxing and waning) pain. The pain builds to a crescendo over minutes to hours, reflecting the build-up of pressure in the obstructed ureter. A key distinguishing feature is the patient's behavior: unlike patients with peritonitis who lie perfectly still, patients with renal colic are typically restless, agitated, and constantly writhing, unable to find any position that provides relief (6, 68).
Pain Radiation (Roadmap of the Stone): The location and radiation of the pain provide a reliable map of the stone's journey down the ureter, a critical piece of information for the examining physician.
Upper Ureter (at UPJ): Obstruction here causes distension of the renal capsule, resulting in a deep, aching pain localized to the flank and costovertebral angle (CVA) (6).
Mid-Ureter: As the stone travels down, the pain follows the path of the genitofemoral nerve, radiating anteriorly across the abdomen and inferiorly toward the iliac fossa. On the right, this can perfectly mimic the presentation of acute appendicitis; on the left, it can be mistaken for diverticulitis (20).
Distal Ureter (at VUJ): When the stone reaches the narrowest part of the ureter where it enters the bladder (the ureterovesical junction), the pain is referred to the groin, testicle, or labia majora. Crucially, irritation of the adjacent bladder wall at this location often triggers a cluster of lower urinary tract symptoms (LUTS), including urinary frequency, urgency, and dysuria, which can be easily misdiagnosed as a simple urinary tract infection (UTI) if a high index of suspicion is not maintained (20).
Common and Red Flag Symptoms
Common Symptoms:
Nausea and Vomiting (~50%): A reflex response mediated by shared autonomic innervation between the kidney and the gut (celiac plexus) (20).
Hematuria (gross or microscopic) (~85-90%): Caused by the stone physically abrading the delicate urothelial lining. However, its absence does not rule out a stone (20).
⚠️ Red Flag Signs & Symptoms:
Fever, Chills, Rigors: The combination of urinary obstruction and infection is a urological emergency. These signs strongly suggest an infected, obstructed kidney (pyonephrosis) or impending urosepsis. Bacteria trapped in the stagnant, pressurized urine behind the stone can easily translocate into the bloodstream, leading to life-threatening sepsis. This situation requires immediate urological consultation for urgent drainage (15).
Complications
Acute:
Urosepsis: A life-threatening systemic infection arising from an obstructed, infected kidney.
Pyonephrosis: Pus under pressure within the renal collecting system, which can rapidly destroy the kidney.
Acute Kidney Injury (AKI): Can result from severe obstruction, especially in a patient with a solitary kidney or pre-existing renal impairment.
Chronic:
Recurrent UTIs: Stones can act as a nidus for persistent bacterial colonization.
Chronic Kidney Disease (CKD): Persistent obstruction and chronic inflammation can lead to progressive renal scarring and loss of function.
Ureteral Stricture: Scarring and narrowing of the ureter, often a late complication of stone impaction or surgical intervention.
Prognosis
Urolithiasis is a chronic disease defined by its high rate of recurrence. Without targeted preventive therapy, up to 53% of patients in Asia will experience another stone event within five years (13). The long-term prognosis is excellent if the underlying metabolic cause is identified and treated, and if the patient adheres strictly to preventive strategies, particularly increased fluid intake.
Differential Diagnosis
Appendicitis: This is the most critical differential for a right-sided mid-ureteric stone. While both can cause right lower quadrant pain, appendicitis is typically associated with a more constant pain, fever, and localized signs of peritonitis (rebound tenderness, guarding). In contrast, colic patients are restless and often have a soft abdomen between spasms (20).
Diverticulitis: A left-sided mid-ureteric stone can mimic the pain of acute diverticulitis. However, diverticulitis is more likely to be associated with a change in bowel habits, localized tenderness, and signs of inflammation on CT imaging (20).
Ovarian Torsion / Ruptured Ovarian Cyst: In female patients, these gynecological emergencies can present with sudden, severe flank or lower abdominal pain. A key differentiator is that the pain is often exacerbated by movement. A pelvic ultrasound is crucial for diagnosis.
Pyelonephritis: A bacterial infection of the kidney itself presents with flank pain, fever, and CVA tenderness. However, the pain is typically a constant, dull ache rather than the sharp, colicky pain of an obstructing stone. Urinalysis will show definitive signs of infection (leukocytes, nitrites, bacteria), but imaging is needed to rule out a co-existing obstructive stone.
Investigations
Immediate & Bedside Tests
Urinalysis (Urine Dipstick): This is a mandatory, rapid first test. It is used to detect hematuria, which strongly supports the diagnosis (present in ~85-90% of cases), and to screen for infection (leukocytes, nitrites) (10, 20). A positive result for infection is a red flag. The urine pH provides a valuable clue to the stone type: a pH < 5.5 is highly suggestive of uric acid stones, while a pH > 7.0 points towards struvite (infection) or calcium phosphate stones (10).
Diagnostic Workup
First-Line Investigations:
Blood Tests: An urgent Renal Function Test (Urea, Electrolytes, Creatinine) is essential to assess for acute kidney injury (AKI) caused by obstruction, which would necessitate urgent intervention (20). A Full Blood Count (FBC) is needed to check for leukocytosis (an elevated white blood cell count), which supports a diagnosis of co-existing infection (20). Serum calcium and uric acid levels should be checked as a baseline metabolic screen, as they can reveal underlying conditions like hyperparathyroidism or gout (28).
Ultrasound (US): This is the first-line imaging modality for pregnant women and children to completely avoid radiation exposure (10). It is excellent for detecting hydronephrosis (the key secondary sign of obstruction) and for visualizing stones within the kidney or at the very bottom of the ureter (at the VUJ). However, its major limitation is that the mid-ureter is often obscured by overlying bowel gas, making it unreliable for detecting stones in this common location (73).
Gold Standard:
Non-Contrast CT of Kidneys, Ureters, Bladder (NCCT KUB): This is the undisputed definitive diagnostic test for non-pregnant adults presenting with acute flank pain. Its diagnostic power is immense: it has exceptional sensitivity (>95%) and specificity (>96%) for detecting stones of all compositions (including radiolucent uric acid stones), sizes, and locations (the rationale). This allows for precise, immediate treatment planning and confidently rules out other serious causes of abdominal pain like appendicitis or diverticulitis (the action) (73, 75).
Monitoring & Staging
Plain X-ray (KUB): While obsolete for initial diagnosis due to its poor sensitivity and inability to visualize radiolucent stones, it remains an excellent, low-cost, low-radiation tool to monitor the progress of a known radio-opaque stone during a trial of conservative management or to assess fragmentation after treatment like ESWL (56).
24-Hour Urine Metabolic Evaluation: This is the cornerstone of effective recurrence prevention for high-risk or recurrent stone formers. The patient collects all urine passed over a 24-hour period, which is then analyzed for volume, pH, and levels of promoters (calcium, oxalate, uric acid) and inhibitors (citrate) (the rationale). This detailed metabolic snapshot allows the clinician to pinpoint the specific underlying abnormality and prescribe targeted dietary and pharmacological therapy (the action) (11, 28).
Stone Analysis: It is imperative that any passed or surgically removed stone be sent for formal analysis (e.g., via infrared spectroscopy). Knowing the precise chemical composition of the stone is fundamental to guiding specific and effective preventive strategies (the rationale), as the prevention for a uric acid stone is completely different from that for a calcium oxalate stone (the action) (10).
Management
Management Principles
The management of urolithiasis is tailored to the clinical scenario and is guided by three core principles: 1) acute symptom control, 2) definitive stone clearance when necessary, and 3) long-term prevention of recurrence.
Acute Stabilisation (The First Hour)
Analgesia: Parenteral NSAIDs (e.g., IV/IM Ketorolac 30mg or Diclofenac 75mg) are the undisputed first-line treatment for renal colic. They provide superior pain relief because they directly target the underlying pathophysiology by inhibiting prostaglandin synthesis (the rationale). This reduces ureteric smooth muscle spasm, inflammation, and intra-renal pressure, thereby alleviating the source of the pain (the action) (6, 17). Opioids are reserved as a second-line option for refractory pain or when NSAIDs are contraindicated (e.g., severe renal impairment).
Antiemetics: Administer an antiemetic like IV Metoclopramide 10mg to effectively manage the common symptoms of nausea and vomiting. This improves patient comfort and is essential for allowing potential oral intake of fluids and medications (20).
Hydration: A critical and often misunderstood point: Avoid aggressive fluid resuscitation or "forcing fluids" during an acute obstructive episode. The pain of colic is caused by pressure. Rapidly increasing urine output will only increase the pressure behind the stone, exacerbating the pain (65). The patient should be advised to drink to comfort to maintain normal hydration, but not to force fluids.
Medical Expulsive Therapy (MET): For patients with small (≤10 mm) distal ureteric stones who are otherwise stable, prescribe an alpha-1 blocker like Tamsulosin 0.4mg once daily. These drugs selectively relax the smooth muscle of the distal ureter, bladder neck, and prostate (the rationale), which reduces spasm around the stone, facilitating its spontaneous passage and reducing the need for analgesia and hospital readmission (the action) (65, 85).
Definitive Therapy
Intervention to remove a stone is indicated for large stones (>10mm), intractable pain, signs of infection, or failure of a stone to pass after an adequate trial of observation (typically 4-6 weeks).
Extracorporeal Shock Wave Lithotripsy (ESWL): A non-invasive procedure where externally generated, focused shockwaves are used to fragment a stone into passable pieces. It is best suited for smaller (<20mm), non-complex renal stones located in the upper or mid-pole of the kidney (81).
Ureteroscopy (URS) with Laser Lithotripsy: A minimally invasive endoscopic procedure where a thin scope is passed up the ureter to the stone. A laser fiber is then used to fragment the stone under direct vision. This is the first-line treatment for most mid and distal ureteric stones and is an excellent option for renal stones up to 20mm, especially those in the lower pole where ESWL is less effective (48, 81).
Percutaneous Nephrolithotomy (PCNL): The most invasive of the main techniques, involving direct percutaneous access into the kidney through a small incision in the flank. This is the undisputed gold standard for large (>20mm) and complex renal stones, such as partial or complete staghorn calculi, as it allows for the most efficient and complete removal of a large stone burden in a single session (48, 81).
Supportive & Symptomatic Care
Continue scheduled or as-needed analgesia to maintain patient comfort.
Instruct the patient to strain all urine using a simple tea strainer or gauze to catch any passed stone fragments for analysis.
Provide clear "sick day" instructions on when to return immediately to the emergency department.
Key Nursing & Monitoring Instructions
Strict hourly or two-hourly monitoring of vital signs, with a low threshold to report any fever, drop in blood pressure, or rise in heart rate, as these can be the first signs of developing sepsis.
Meticulously monitor urine output. Anuria (no urine output) or oliguria (<0.5mL/kg/hr) is a urological emergency that may signify complete obstruction or AKI.
Maintain a strict input/output chart to guide fluid management.
Inform the medical team immediately if the patient develops a fever, becomes hemodynamically unstable, or if their pain becomes uncontrolled despite analgesia.
Long-Term Plan & Patient Education
Hydration is Key: This is the single most effective preventive measure for all stone types. The patient must be counseled to increase their fluid intake (preferably water) consistently throughout the day to achieve a target urine output of at least 2.5 liters per day. A practical tip is to aim for urine that is always clear or pale yellow (11).
Dietary Modification: Specific advice must be tailored to the patient's stone type and 24-hour urine results.
Calcium Oxalate Stones: The cornerstones are to limit sodium intake (<2,300 mg/day) and limit non-dairy animal protein. Crucially, patients must be educated to maintain a normal dietary calcium intake (1,000-1,200 mg/day, consumed with meals) to bind oxalate in the gut and prevent its absorption (11).
Uric Acid Stones: The primary focus is to limit intake of high-purine foods, such as red meat, organ meats (liver, kidneys), and certain shellfish.
Pharmacological Prevention: For high-risk recurrent formers, medication is often necessary.
Thiazide diuretics (e.g., hydrochlorothiazide, chlorthalidone) are prescribed to reduce urinary calcium excretion in patients with persistent hypercalciuria.
Potassium citrate is used to correct hypocitraturia (low citrate) and to alkalinize the urine (raise pH), which is the primary treatment for preventing uric acid stones.
Allopurinol is a second-line agent used to reduce uric acid production in patients with hyperuricosuria who continue to form stones despite dietary changes and alkalinization (11).
When to Escalate
Call Your Senior (MO/Specialist) if:
The patient has any signs of urosepsis (fever >38°C, hypotension, tachycardia, confusion). This is a time-critical urological emergency requiring immediate fluid resuscitation, antibiotics, and urgent surgical decompression of the obstructed kidney.
The patient has a significantly elevated or rising creatinine indicating acute kidney injury (AKI) or develops anuria (no urine output for several hours).
The patient has an obstructing stone in a solitary or transplanted kidney, as any obstruction in this setting can lead to rapid and irreversible loss of renal function.
Pain is intractable and cannot be controlled with appropriate doses of both NSAIDs and opioids.
The patient is unable to tolerate any oral intake due to persistent vomiting, leading to dehydration.
References
Urolithiasis: History, epidemiology, aetiologic factors and management - Mjpath.org.my. (2023). Retrieved July 13, 2025, from https://mjpath.org.my/2023/v45n3/urolithiasis.pdf
Urolithiasis and Its Causes- Short Review - The Journal of Phytopharmacology. (n.d.). Retrieved July 13, 2025, from https://www.phytopharmajournal.com/V2issue3010.pdf
Chandrakanta. (2025). Urolithiasis An Update on Epidemiology Diagnosis And Treatment Options. International Journal of Pharmaceutical Sciences, 3(7), 776-782. Retrieved from https://www.ijpsjournal.com/assetsbackoffice/uploads/article/Urolithiasis+An+Update+on+Epidemiology+Diagnosis+And+Treatment+Options.pdf
Assessment of the prevalence of kidney stone diseases in a Malaysian teaching hospital. (2018). ResearchGate. Retrieved July 13, 2025, from https://www.researchgate.net/publication/327263646_Assessment_of_the_prevalence_of_kidney_stone_diseases_in_a_Malaysian_teaching_hospital
Kidney Stone Pathophysiology, Evaluation and Management: Core Curriculum 2023. (2023). PMC. Retrieved July 13, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC11370273/
Urolithiasis. (2023). StatPearls - NCBI Bookshelf. Retrieved July 13, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK559101/
What is Urolithiasis? (n.d.). News-Medical.net. Retrieved July 13, 2025, from https://www.news-medical.net/health/What-is-Urolithiasis.aspx
Knowledge, Awareness and Practice on Dietary Management among Patients with Urolithiasis: A Scoping Review. (2022). IIUM Journals. Retrieved July 13, 2025, from https://journals.iium.edu.my/ijcs/index.php/ijcs/article/download/252/139/1341
Seminar Kidney stones: pathophysiology and medical management. (n.d.). CiteSeerX. Retrieved July 13, 2025, from https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=3ecf4034b4c69aa5961721e9435ba699730a8ea0
EAU Guidelines on Urolithiasis. (2024). Uroweb - European Association of Urology. Retrieved July 13, 2025, from https://uroweb.org/guidelines/urolithiasis/chapter/guidelines
Kidney Stones: Medical Mangement Guideline. (2024). American Urological Association. Retrieved July 13, 2025, from https://www.auanet.org/guidelines-and-quality/guidelines/kidney-stones-medical-mangement-guideline
Epidemiology of urolithiasis in Asia. (2018). Asian Journal of Urology. Retrieved July 13, 2025, from http://www.ajurology.com/EN/10.1016/j.ajur.2018.08.007
Kidney stones - Symptoms, causes, types, and treatment. (n.d.). National Kidney Foundation. Retrieved July 13, 2025, from https://www.kidney.org/kidney-topics/kidney-stones
The Management of Urolithiasis. (2019). U.S. Pharmacist. Retrieved July 13, 2025, from https://www.uspharmacist.com/article/the-management-of-urolithiasis
What are the causes, risk factors, preventive measures, signs and symptoms, and treatment options for Kidney Stone (Urolithiasis) disease? (n.d.). Dr.Oracle AI. Retrieved July 13, 2025, from https://www.droracle.ai/articles/11012/urolithiasis-cause-risk-factors-preventive-measures-signs-and-symptoms-and-treatment
Kidney stones - Symptoms and causes. (2022). Mayo Clinic. Retrieved July 13, 2025, from https://www.mayoclinic.org/diseases-conditions/kidney-stones/symptoms-causes/syc-20355755
Urolithiasis. (n.d.). WikEM. Retrieved July 13, 2025, from https://wikem.org/wiki/Urolithiasis
Recent advances on the mechanisms of kidney stone formation. (2021). Spandidos Publications. Retrieved July 13, 2025, from https://www.spandidos-publications.com/10.3892/ijmm.2021.4982
Medical evaluation and management of urolithiasis. (2011). PMC - PubMed Central. Retrieved July 13, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC3126068/
Inflammation and kidney stones: cause and effect? (2022). ResearchGate. Retrieved July 13, 2025, from https://www.researchgate.net/publication/366594781_Inflammation_and_kidney_stones_cause_and_effect
Targeting the NLRP3 inflammasome for calcium oxalate stones: pathophysiology and emerging pharmacological interventions. (2025). Frontiers. Retrieved July 13, 2025, from https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2025.1614438/full
Dietary oxalate and kidney stone formation. (2019). PMC. Retrieved July 13, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC6459305/
Epidemiology of urolithiasis in Asia. (2018). PMC - PubMed Central. Retrieved July 13, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC6197415/
Kidney Ureteric and Bladder Stones. (n.d.). Urology Malaysia. Retrieved July 13, 2025, from https://www.urology.com.my/kidney-ureteric-and-bladder-stones/
Prevalence of urolithiasis in Sarawak and associated risk factors: An ultrasonagraphy‐based cross‐sectional study. (2022). PMC. Retrieved July 13, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC9766857/
The metabolic syndrome and urolithiasis: a systematic review. (2015). Taylor & Francis Online. Retrieved July 13, 2025, from https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.976133
Evaluation of genetic associations with clinical phenotypes of kidney stone disease. (2024). medRxiv. Retrieved July 13, 2025, from https://www.medrxiv.org/content/10.1101/2024.01.18.24301501v1.full-text
Urolithiasis – Ten things every general practitioner should know. (2017). RACGP. Retrieved July 13, 2025, from https://www.racgp.org.au/afp/2017/september/urolithiasis
Genetic Polymorphisms and Kidney Stones Around the Globe: A Systematic Review and Meta-Analysis. (2022). PubMed Central. Retrieved July 13, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC9280078/
Kidney Stones: Treatment and Prevention. (2019). AAFP. Retrieved July 13, 2025, from https://www.aafp.org/pubs/afp/issues/2019/0415/p490.html
Urolithiasis : Disease Summary. (n.d.). MIMS Malaysia. Retrieved July 13, 2025, from https://www.mims.com/malaysia/disease/urolithiasis/disease-summary
Comparison of CT Scan, X-Ray and Ultrasound in Sensitivity and Specificity for Identifying Kidney Stones in Clinical Settings: A Comprehensive Systematic Review. (2023). ResearchGate. Retrieved July 13, 2025, from https://www.researchgate.net/publication/392382345_Comparison_of_CT_Scan_X-Ray_and_Ultrasound_in_Sensitivity_and_Specificity_for_Identifying_Kidney_Stones_in_Clinical_Settings_A_Comprehensive_Systematic_Review
Advances in CT imaging for urolithiasis. (2015). PMC. Retrieved July 13, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC4495492/
Kidney Stones: Surgical Management Guideline. (2016). American Urological Association. Retrieved July 13, 2025, from https://www.auanet.org/guidelines-and-quality/guidelines/kidney-stones-surgical-management-guideline
Medical Expulsive Therapy -Reviewing the Pharmacological and Therapeutic Potential of Combining Tamsulosin and Deflazacort. (2024). ResearchGate. Retrieved July 13, 2025, from https://www.researchgate.net/publication/393401209_Medical_Expulsive_Therapy_-Reviewing_the_Pharmacological_and_Therapeutic_Potential_of_Combining_Tamsulosin_and_Deflazacort
